. | . |
Black, Hispanic cancer clinical trial enrollment starts to rise by Sommer Brokaw Washington DC (UPI) Nov 22, 2021 Black and Hispanic participation in various cancer clinical trials has increased in recent years, but both populations remain underrepresented, researchers said in a study published Monday in the journal Cancer. Black and Hispanic patients were more likely now to participate in breast, lung and prostate cancer trials from 2015-2019 than they were to participate in trials from 2000-2004, according to the analysis of data from the National Cancer Institute. The study found that women and older people also are underrepresented in trials for some types of cancer. Inclusion of people from diverse backgrounds can show whether or not treatments are safe and effective for people with different characteristics, researchers said. "Our article indicates that the disparity for clinical enrollment in NCI clinical trials has narrowed for minorities, but further efforts are still needed," lead study author Dr. Juan F. Javier-Desloges, a urologist at the University of California-San Diego, said in a press release. The new study, using data from NCI's Clinical Data Update System, which contains data from the trials sponsored by the agency, compared trial participation to cancer incidence rates. Researchers reviewed data on 242,720 participants, 81.3% of whom were non-Hispanic White, 8.7% were Black, 4.8% were Hispanic and 2.8% were of Asian or Pacific Islander descent. The analysis found that Black and Hispanic patients were more likely to participate in breast cancer trials from 2015-2019 than they were from 2000-2004, but were underrepresented in colorectal, lung and prostate cancer trials. Older patients were also underrepresented in breast, colorectal, and lung cancer trials in comparisons of the two time periods, researchers said, and women were underrepresented in colorectal and lung cancer trials. The study follows a growing body of evidence suggesting race and ethnicity could be key factors in predicting how patients will respond to a drug. For example, researchers at an academic medical center in New York City found in a 2015 study that angiotensin-converting-enzyme, or ACE, inhibitors, were associated with significantly worse health outcomes in Black patients than in White patients. A study last year by University of Alabama at Birmingham study found that racial bias persists in recruitment for cancer clinical trials.Dr. Reagan Durant, an assistant professor at UAB's Division of Preventative Medicine and lead author on the 2020 study, said at the time that the significance of his findings "rests in the notion that biases potentially exist in all forms of human interaction, and recruitment for cancer research studies is not exception." "Once we acknowledge the potential presence of this bias in this context, we can better identify it, measure it and begin to think about how best to address it," Durant said.
Chemical in human body odor triggers aggression in women, but not men Washington DC (UPI) Nov 19, 2021 Sniffing a chemical in human body odor blocks aggression in men but triggers it in women, an analysis published Friday by the journal Science Advances found. The chemical in question, called hexadecanal, or HEX, is also emitted by infants when under stress, the researchers said. This may be why the odor it produces leads to more aggressive behavior in women, as it taps into the maternal instinct to protect their offspring, according to the researchers. At the same time, the HEX sc ... read more
|
|
The content herein, unless otherwise known to be public domain, are Copyright 1995-2024 - Space Media Network. All websites are published in Australia and are solely subject to Australian law and governed by Fair Use principals for news reporting and research purposes. AFP, UPI and IANS news wire stories are copyright Agence France-Presse, United Press International and Indo-Asia News Service. ESA news reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. All articles labeled "by Staff Writers" include reports supplied to Space Media Network by industry news wires, PR agencies, corporate press officers and the like. Such articles are individually curated and edited by Space Media Network staff on the basis of the report's information value to our industry and professional readership. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space Media Network on any Web page published or hosted by Space Media Network. General Data Protection Regulation (GDPR) Statement Our advertisers use various cookies and the like to deliver the best ad banner available at one time. All network advertising suppliers have GDPR policies (Legitimate Interest) that conform with EU regulations for data collection. By using our websites you consent to cookie based advertising. If you do not agree with this then you must stop using the websites from May 25, 2018. Privacy Statement. Additional information can be found here at About Us. |